펩타이드 및 올리고뉴클레오티드 CDMO 시장 보고서 : 동향, 예측 및 경쟁 분석(-2030년)

Peptide and Oligonucleotide CDMO Trends and Forecast

The future of the global peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets. The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030 with a CAGR of 11.3% from 2024 to 2030. The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Peptide and Oligonucleotide CDMO by Segment

The study includes a forecast for the global peptide and oligonucleotide CDMO by product, service type, end use, and region.

Peptide and Oligonucleotide CDMO Market by Product [Shipment Analysis by Value from 2018 to 2030]:

• Peptides
• Oligonucleotides

Peptide and Oligonucleotide CDMO Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:

• Contract Development
• Contract Manufacturing

Peptide and Oligonucleotide CDMO Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others

Peptide and Oligonucleotide CDMO Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Peptide and Oligonucleotide CDMO Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peptide and oligonucleotide CDMO companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peptide and oligonucleotide CDMO companies profiled in this report include-

• PolyPeptide Group
• STA Pharmaceutical
• Bachem
• Creative Peptides
• Aurigene Pharmaceutical Services
• Merck
• EUROAPI
• Curia Global
• CordenPharm
• Sylentis

Peptide and Oligonucleotide CDMO Market Insights

Lucintel forecasts that peptide will remain larger segment over the forecast period.

Within this market, biopharmaceutical company will remain larger segment over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global Peptide and Oligonucleotide CDMO Market

Market Size Estimates: Peptide and oligonucleotide CDMO market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peptide and oligonucleotide CDMO market size by product, service type, end use, and region in terms of value ($B).

Regional Analysis: Peptide and oligonucleotide CDMO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, service types, end uses, and regions for the peptide and oligonucleotide CDMO market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide and oligonucleotide CDMO market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the peptide and oligonucleotide CDMO market size?

Answer: The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030.

Q2. What is the growth forecast for peptide and oligonucleotide CDMO market?

Answer: The global peptide and oligonucleotide CDMO market is expected to grow with a CAGR of 11.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the peptide and oligonucleotide CDMO market?

Answer: The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

Q4. What are the major segments for peptide and oligonucleotide CDMO market?

Answer: The future of the peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets.

Q5. Who are the key peptide and oligonucleotide CDMO market companies?

Answer: Some of the key peptide and oligonucleotide CDMO companies are as follows:

• PolyPeptide Group
• STA Pharmaceutical
• Bachem
• Creative Peptides
• Aurigene Pharmaceutical Services
• Merck
• EUROAPI
• Curia Global
• CordenPharm
• Sylentis

Q6. Which peptide and oligonucleotide CDMO market segment will be the largest in future?

Answer: Lucintel forecasts that peptide will remain larger segment over the forecast period.

Q7. In peptide and oligonucleotide CDMO market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the peptide and oligonucleotide CDMO market by product (peptides and oligonucleotides), service type (contract development and contract manufacturing), end use (pharmaceutical companies, biopharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peptide and Oligonucleotide CDMO Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Peptide and Oligonucleotide CDMO Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Peptide and Oligonucleotide CDMO Market by Product
  • 3.3.1: Peptides
  • 3.3.2: Oligonucleotides
• 3.4: Global Peptide and Oligonucleotide CDMO Market by Service Type
  • 3.4.1: Contract Development
  • 3.4.2: Contract Manufacturing
• 3.5: Global Peptide and Oligonucleotide CDMO Market by End Use
  • 3.5.1: Pharmaceutical Companies
  • 3.5.2: Biopharmaceutical Companies
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Peptide and Oligonucleotide CDMO Market by Region
• 4.2: North American Peptide and Oligonucleotide CDMO Market
  • 4.2.1: North American Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
  • 4.2.2: North American Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
• 4.3: European Peptide and Oligonucleotide CDMO Market
  • 4.3.1: European Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
  • 4.3.2: European Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
• 4.4: APAC Peptide and Oligonucleotide CDMO Market
  • 4.4.1: APAC Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
  • 4.4.2: APAC Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
• 4.5: ROW Peptide and Oligonucleotide CDMO Market
  • 4.5.1: ROW Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
  • 4.5.2: ROW Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Product
  • 6.1.2: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Service Type
  • 6.1.3: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by End Use
  • 6.1.4: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Region
• 6.2: Emerging Trends in the Global Peptide and Oligonucleotide CDMO Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Peptide and Oligonucleotide CDMO Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peptide and Oligonucleotide CDMO Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: PolyPeptide Group
• 7.2: STA Pharmaceutical
• 7.3: Bachem
• 7.4: Creative Peptides
• 7.5: Aurigene Pharmaceutical Services
• 7.6: Merck
• 7.7: EUROAPI
• 7.8: Curia Global
• 7.9: CordenPharm
• 7.10: Sylentis